2. Immunology/Inflammation Epigenetics Cell Cycle/DNA Damage Cytoskeleton Neuronal Signaling
  3. COX HDAC Microtubule/Tubulin Interleukin Related Amyloid-β Tau Protein
  4. COX-2/HDAC6-IN-1

COX-2/HDAC6-IN-1 (Compound 11e) is a dual COX-2 and HDAC6 inhibitor, with an IC50 of 0.12 μM against HDAC6 and an IC50 of 0.66 μM against COX-2. COX-2/HDAC6-IN-1 enhances the acetylation level of α-tubulin, regulates epigenetic gene expression, and inhibits the expression of pro-inflammatory mediators (COX-2, IL-1β, IL-6 and TNF-α). COX-2/HDAC6-IN-1 promotes Amyloid-β clearance and reduces excessive phosphorylation of Tau protein. COX-2/HDAC6-IN-1 maintains neuronal morphology by stabilizing MAP2, protects synaptic integrity by regulating synapsin, and restores the expression of memory-related genes. COX-2/HDAC6-IN-1 possesses neuroprotective activity and improves learning and memory abilities in Scopolamine (HY-N0296)-induced Alzheimer's disease mouse models. COX-2/HDAC6-IN-1 is applicable to research related to Alzheimer's disease.

For research use only. We do not sell to patients.

COX-2/HDAC6-IN-1

COX-2/HDAC6-IN-1 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

COX-2/HDAC6-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3

View All HDAC Isoform Specific Products:

View All Isoforms
HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

COX-2/HDAC6-IN-1 (Compound 11e) is a dual COX-2 and HDAC6 inhibitor, with an IC50 of 0.12 μM against HDAC6 and an IC50 of 0.66 μM against COX-2. COX-2/HDAC6-IN-1 enhances the acetylation level of α-tubulin, regulates epigenetic gene expression, and inhibits the expression of pro-inflammatory mediators (COX-2, IL-1β, IL-6 and TNF-α). COX-2/HDAC6-IN-1 promotes Amyloid-β clearance and reduces excessive phosphorylation of Tau protein. COX-2/HDAC6-IN-1 maintains neuronal morphology by stabilizing MAP2, protects synaptic integrity by regulating synapsin, and restores the expression of memory-related genes. COX-2/HDAC6-IN-1 possesses neuroprotective activity and improves learning and memory abilities in Scopolamine (HY-N0296)-induced Alzheimer's disease mouse models. COX-2/HDAC6-IN-1 is applicable to research related to Alzheimer's disease[1].

IC50 & Target[1]

HDAC6

0.12 μM (IC50)

COX-2

0.66 μM (IC50)

IL-6

 

IL-1β

 

In Vitro

COX-2/HDAC6-IN-1 potently inhibits HDAC6 (IC50 = 0.12 μM) and COX-2 (IC50 = 0.66 μM)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

COX-2/HDAC6-IN-1 Related Antibodies
In Vivo

COX-2/HDAC6-IN-1 (1 mg/kg/day; intraperitoneal injection; 14 days) improves learning and memory abilities in Scopolamine (HY-N0296)-induced Alzheimer's disease mouse models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: albino mice (male, 8-10 weeks old, 30-35 g, scopolamine-induced AD model)[1]
Dosage: 1 mg/kg/day
Administration: i.p.; 14 days
Result: Produced a 4.3-fold increase in spontaneous alternation percentage in the Y-maze test compared to the scopolamine-induced AD group, and a 2.2-fold and 3.6-fold increase compared to the compound 10a and 11a groups, respectively.
Reduced the time to reach the ground in the pole climbing test by 42.3% compared to the scopolamine-induced AD group, with times 27% and 11.4% lower than the compound 10a and 11a groups, respectively.
Decreased GFAP gene expression by 54.7% (to 1.019 ± 0.05 RCN) compared to the scopolamine-induced AD group.
Increased MAP2 gene expression by 46.5% (to 0.747 ± 0.03 RCN) compared to the scopolamine-induced AD group.
Increased synaptophysin gene expression by 39.2% (to 0.891 ± 0.08 RCN) compared to the scopolamine-induced AD group.
Reduced Aβ1-40 concentration to 19.71 ± 2.13 pg/mg protein (62.41% decrease) compared to the scopolamine-induced AD group.
Reduced IL-1β concentration to 1.8 ± 0.4 pg/mg protein (71.8% decrease) compared to the scopolamine-induced AD group.
Reduced IL-6 concentration to 6.96 ± 1.55 pg/mg protein (67.7% decrease) compared to the scopolamine-induced AD group.
Reduced TNF-α concentration to 59.55 ± 3.17 ng/mg protein (65.07% decrease) compared to the scopolamine-induced AD group.
Increased acetylated histone H3 protein expression by 2-fold (to 0.7 ± 0.04 pg/mg protein) compared to the scopolamine-induced AD group.
Increased acetylated α-tubulin protein expression by 3.03-fold (to 1 ± 0.048 pg/mg protein) compared to the scopolamine-induced AD group.
Reduced COX-2 protein expression by 33.5% (to 0.355 ± 0.02 pg/mg protein) compared to the scopolamine-induced AD group.
Reduced MDA levels by 75% (to 1.3 ± 0.08 nmol/mg protein) compared to the scopolamine-induced AD group.
Increased GSH levels by 2.05-fold (to 7 ± 0.31 nmol/mg protein) compared to the scopolamine-induced AD group.
Reduced NO concentration by 83.2% (to 1.98 ± 0.23 μmol/mg protein) compared to the scopolamine-induced AD group.
Restored semi-normal histoarchitecture of the cerebral cortex with minimal pyknotic nuclei and pericellular edema; increased pyramidal cell counts and reduced total histopathologic scoring compared to the scopolamine-induced AD group.
Reduced insoluble Aβ plaque staining to 0.346 ± 0.108 compared to the scopolamine-induced AD group.
Reduced phosphorylated Tau immunoreactivity to 0.277 ± 0.066 (nearly normal levels) compared to the scopolamine-induced AD group.
Reduced phosphorylated STAT3 (705) expression to mild levels compared to the scopolamine-induced AD group.
Molecular Weight

487.53

Formula

C23H25N3O7S
SMILES

COC1=C(OC)C=CC(C2=CC(C(NCC(OCC)=O)=O)=NN2C3=CC=C(S(=O)(C)=O)C=C3)=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

COX-2/HDAC6-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

COX-2/HDAC6-IN-1COXHDACMicrotubule/TubulinInterleukin RelatedAmyloid-βTau ProteinCyclooxygenaseHistone deacetylasesILβ-amyloid peptideAβAbetaIL-1βHDAC6amyloid-βα-tubulinIL-6Alzheimer's diseaseTNF-αSTAT3COX-2TauInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
COX-2/HDAC6-IN-1
Cat. No.:
HY-181926
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.